These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23099813)

  • 1. Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice.
    Peters OM; Connor-Robson N; Sokolov VB; Aksinenko AY; Kukharsky MS; Bachurin SO; Ninkina N; Buchman VL
    J Alzheimers Dis; 2013; 33(4):1041-9. PubMed ID: 23099813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic administration of Dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice.
    Peters OM; Shelkovnikova T; Tarasova T; Springe S; Kukharsky MS; Smith GA; Brooks S; Kozin SA; Kotelevtsev Y; Bachurin SO; Ninkina N; Buchman VL
    J Alzheimers Dis; 2013; 36(3):589-96. PubMed ID: 23645096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.
    Shelkovnikova TA; Ustyugov AA; Millership S; Peters O; Anichtchik O; Spillantini MG; Buchman VL; Bachurin SO; Ninkina NN
    Neurodegener Dis; 2011; 8(6):430-7. PubMed ID: 21576917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.
    Bachurin SO; Shelkovnikova TA; Ustyugov AA; Peters O; Khritankova I; Afanasieva MA; Tarasova TV; Alentov II; Buchman VL; Ninkina NN
    Neurotox Res; 2012 Jul; 22(1):33-42. PubMed ID: 22179976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice.
    Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I
    Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Property of Dimebon as a Neuroprotective Agent.
    Ustyugov A; Shevtsova E; Ashraf GM; Tarasov VV; Bachurin SO; Aliev G
    Curr Med Chem; 2018; 25(39):5315-5326. PubMed ID: 27494393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice.
    Zhang YH; Wang DW; Xu SF; Zhang S; Fan YG; Yang YY; Guo SQ; Wang S; Guo T; Wang ZY; Guo C
    Redox Biol; 2018 Apr; 14():535-548. PubMed ID: 29126071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
    Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
    J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
    Rodríguez-Navarro JA; Rodríguez L; Casarejos MJ; Solano RM; Gómez A; Perucho J; Cuervo AM; García de Yébenes J; Mena MA
    Neurobiol Dis; 2010 Sep; 39(3):423-38. PubMed ID: 20546895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
    Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
    BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.
    Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ
    Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study into molecular targets of a neuroprotective compound dimebon using a transgenic mice line].
    Shelkovnikova TA; Ustiugov AA; Kokhan VS; Tarasova TV; Medvedeva VK; Khritankova IV; Bachurin SO; Ninkina NN
    Biomed Khim; 2014; 60(3):354-63. PubMed ID: 25019398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
    Brunden KR; Trojanowski JQ; Lee VM
    Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).
    Ustyugov A; Shevtsova E; Bachurin S
    Mol Neurobiol; 2015 Oct; 52(2):970-8. PubMed ID: 26123670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alpha-tocopherol on an animal model of tauopathies.
    Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
    Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound.
    Baazaoui N; Iqbal K
    J Alzheimers Dis; 2017; 58(1):215-230. PubMed ID: 28387677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.
    Wagner J; Krauss S; Shi S; Ryazanov S; Steffen J; Miklitz C; Leonov A; Kleinknecht A; Göricke B; Weishaupt JH; Weckbecker D; Reiner AM; Zinth W; Levin J; Ehninger D; Remy S; Kretzschmar HA; Griesinger C; Giese A; Fuhrmann M
    Acta Neuropathol; 2015 Nov; 130(5):619-31. PubMed ID: 26439832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.